Urgent Call for Universal Diabetes Care in Europe Amidst Political Apathy

By João L. Carapinha

November 25, 2024

The article from Euractiv titled “Universal access to diabetes care urgently needed in Europe, but political will is lacking” highlights several critical issues and recommendations regarding diabetes care in Europe. The growing challenge of diabetes across the continent highlights the urgent need for universal access to diabetes care. With 32 million people living with diabetes, one-third of whom remain undiagnosed, the situation demands immediate attention and action.

Current State of Diabetes Care in Europe

The article emphasizes that diabetes is a significant and growing health challenge in Europe, affecting millions and indicating a pressing need for universal access to diabetes care.

Lack of Political Will

Despite the severity of the issue, there is a lack of sufficient political will to address diabetes comprehensively. While there is growing awareness and enthusiasm from MEPs, more must be done to ensure that diabetes receives the prioritization it needs within the European health agenda.

Key Objectives of IDF Europe

The International Diabetes Federation (IDF) Europe has three main priorities:

– Keeping the person living with diabetes at the center of all efforts.
– Advocacy to increase awareness and push for stronger prioritization of diabetes within the EU’s health agenda.
– Ensuring universal access to diabetes care, including advanced treatments like continuous glucose monitoring (CGM).

Advocacy and Partnerships

IDF Europe is working in partnership with organizations like the World Health Organization (WHO) Europe to amplify their collective voice and achieve impactful outcomes. Their aim is to unite various groups and build advocates within health systems to ensure universal access to diabetes care for all individuals.

Financial and Resource Challenges

The financial burden of diabetes on health systems is substantial. A significant portion of healthcare budgets are allocated to medications and managing complications. Also, the socio-economic impact, including loss of productivity, is significant.

Calls to Action

IDF Europe is calling for politicians to invest in prevention and early treatment to avert costly and devastating complications. Achieving universal access to diabetes care requires not just financial resources but also a committed effort to place diabetes at the forefront of the European agenda.

Need for Comprehensive Plans

There is a pressing need for a structured plan to turn promises into tangible actions. While resolutions and declarations have been made, a comprehensive approach is necessary to ensure targets for diabetes care are met in the medium to long term.

Healthcare System Improvements

Improving access to healthcare services, medicines, and technologies is crucial. This includes strengthening primary care systems, allocating resources more efficiently, and ensuring uninterrupted and affordable access to necessary treatments and tools.

In summary, the article emphasises the urgent need for universal access to diabetes care in Europe. It identifies gaps in the current healthcare systems, and emphasizes the necessity for strong political will. It also notes that comprehensive plans are needed to effectively tackle the escalating diabetes crisis. Universal access to diabetes care is essential for improving health outcomes across Europe.

Reference url

Recent Posts

FDA Warning Letter Novo Nordisk Reveals Serious Compliance Failures in Adverse Drug Reporting

By João L. Carapinha

March 11, 2026

The U.S. Food and Drug Administration (FDA) issued the FDA Warning Letter Novo Nordisk dated March 5, 2026, to Novo Nordisk Inc. (NNI)...
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review

By João L. Carapinha

March 10, 2026

Economic evaluations of vaccines targeting multi-disease combinations, such as hepatitis A/B or measles-mumps-rubella (MMR), reveal critical methodological shortcomings in this systematic literature review. Synthesiz...
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
Enhertu (trastuzumab deruxtecan), developed by AstraZeneca and Daiichi Sankyo, has received P...